Investment Rating - The investment rating for the company is "Buy" and is maintained [9]. Core Insights - The company reported a revenue of 740 million yuan for the first three quarters of 2025, representing a year-on-year increase of 14.2%. The net profit attributable to shareholders was 230 million yuan, up 15.1% year-on-year, and the net profit after deducting non-recurring gains and losses was 220 million yuan, an increase of 11.7% year-on-year. In Q3 alone, the revenue was 270 million yuan, reflecting a year-on-year growth of 14.8% and a quarter-on-quarter increase of 7.2% [2][6]. - The company is a leading domestic producer of nucleating agents and synthetic hydrotalcite, with aspirations to become a global leader in polymer material solutions. Its core products are gradually replacing imports in the domestic market and are competitive internationally [12]. - The company's gross margin for Q1 to Q3 of 2025 was 45.4%, a year-on-year increase of 0.4 percentage points, while the net margin was 30.8%, up 0.2 percentage points. The operating expense ratio decreased to 9.3%, down 0.4 percentage points year-on-year, driven by reductions in sales and management expense ratios [12]. - The completion of the IPO project and the full operation of the Nansha plant have further enhanced the company's production capacity, adding significant new capacity for nucleating agents and synthetic hydrotalcite [12]. - The company achieved rapid growth in overseas revenue, reaching 120 million yuan in H1 2025, a year-on-year increase of 70.1%. This growth is attributed to the company's international strategy and its ability to meet overseas customer demands [12]. - The company emphasizes shareholder returns, with a mid-year dividend of 43 million yuan announced for 2025, maintaining a payout ratio between 30% and 35% since 2020 [12]. - The company is focused on the polymer material additives sector and has strong competitiveness in antioxidant and NDO composite additives. The domestic market for nucleating agents and synthetic hydrotalcite has low penetration, indicating potential for market share growth [12]. Financial Summary - For 2025, the company forecasts total revenue of 1.058 billion yuan, with net profits projected at 297 million yuan, 333 million yuan, and 377 million yuan for the years 2025, 2026, and 2027 respectively [17].

Core Viewpoint - The report outlines the ongoing supervision and assessment of Chenghe Technology Co., Ltd. by CITIC Securities, highlighting the company's financial performance, potential risks, and core competencies in the polymer materials industry. Group 1: Continuous Supervision Overview - CITIC Securities has taken over the continuous supervision responsibilities from the previous sponsor, conducting various checks and assessments as per regulatory requirements [1]. - The supervision includes reviewing corporate governance documents, financial management systems, and fundraising management practices [1]. Group 2: Financial Performance - The company's operating income for the first half of 2025 reached RMB 471.09 million, representing a 13.77% increase compared to the same period in 2024 [9]. - The net profit attributable to shareholders for the same period was RMB 31.87 million, reflecting a decrease of 21.28% due to an increase in total share capital [9]. Group 3: Major Risks - Intellectual property disputes pose a risk, as the company holds 76 patents but may face litigation or regulatory penalties related to patent infringement [2]. - Core technology leakage is a concern, with 90.94% of revenue derived from products based on proprietary technology [3]. - Product quality control is critical, as any failure in quality management could damage the company's reputation and client trust [3]. - Environmental protection and safety production risks are present due to the chemical processes involved in production, which may lead to regulatory penalties [4]. - The company's gross margin was reported at 45.79%, with potential risks of decline due to various market factors [4]. - Accounts receivable amounted to RMB 318.71 million, representing 67.65% of revenue, indicating a risk of bad debts as sales scale increases [6]. - Currency fluctuations could impact the company's foreign sales, which accounted for 25.39% of total revenue [5]. - The company faces risks related to bank acceptance bills, with RMB 96.13 million in receivables potentially at risk if the creditworthiness of the issuing parties declines [5]. - Increased market competition in the emerging fine chemical sector could affect profitability if the company fails to innovate [6]. Group 4: Core Competitiveness - Chenghe Technology is recognized as a leading enterprise in high-performance polymer materials, focusing on technological innovation and sustainable development [10]. - The company has over 300 types of nucleating agents and composite additives, providing customized solutions to meet client needs [10]. - The core products have achieved international advanced levels, with some exceeding global standards, enhancing the company's competitive edge [10]. - The company has established partnerships with universities for research and development, enhancing its innovation capabilities [12]. - Chenghe Technology has been recognized as a model enterprise for intellectual property in Guangdong Province, with a strong patent portfolio [12]. Group 5: Research and Development - R&D expenditures for the first half of 2025 totaled RMB 21.45 million, a 28.92% increase from the previous year, reflecting a commitment to product innovation [17]. - The company holds 76 valid patents, including 59 invention patents, indicating a robust focus on R&D [18]. - New projects are underway to develop advanced additives and materials, addressing specific market needs and enhancing product performance [19][20].